Mehmood Faizan, Rizvi Syed Ali Raza, Alam Sarah, Ansari Benazir
Department of Ophthalmology, Aster Hospital Al Qusais, Dubai, UAE.
Department of Ophthalmology Oculoplasty and Ocular Oncology Services, Al Nahdha Hospital, Ministry of Health, Muscat, Oman.
Oman J Ophthalmol. 2024 Oct 24;17(3):313-319. doi: 10.4103/ojo.ojo_308_23. eCollection 2024 Sep-Dec.
Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is an autoimmune disorder caused due to a complex interplay between autoantigens including the thyroid-stimulating hormone receptor and the insulin-like growth factor-I receptor. TED is characterized by progressive proptosis or diplopia. This systematic review aimed to compare the efficacy of the newer monoclonal antibody - teprotumumab and intravenous methylprednisolone (IVMP) in TED patients. We performed a systematic review of previously published studies from 2013 to June 2023. A total of 329 articles were screened; among them, 111 non-duplicate publications were identified. After the screening of titles and abstracts, 156 publications were excluded; then, another 47 published papers were excluded after the full-text screening. The remaining 15 eligible studies were included in this systematic review. The majority of studies used either teprotumumab alone or in combination with others. Among 15 studies, eight studies used teprotumumab in TED patients, whereas remaining 7 studies used a standard treatment regimen. This systematic review provides an overview of the existing treatment options using monoclonal antibody - teprotumumab and IVMP in TED patients. The overall assessment provides a finding that antibody - teprotumumab is is a good choice compared to conventional IVMP for providing better outcomes in patients with TED.
甲状腺眼病（TED），也称为甲状腺相关性眼病，是一种自身免疫性疾病，由包括促甲状腺激素受体和胰岛素样生长因子-I受体在内的自身抗原之间的复杂相互作用引起。TED的特征是进行性眼球突出或复视。本系统评价旨在比较新型单克隆抗体——替普罗单抗和静脉注射甲泼尼龙（IVMP）在TED患者中的疗效。我们对2013年至2023年6月发表的先前研究进行了系统评价。共筛选了329篇文章；其中，识别出111篇非重复出版物。在筛选标题和摘要后，排除了156篇出版物；然后，在全文筛选后又排除了47篇已发表论文。其余15项符合条件的研究纳入了本系统评价。大多数研究单独使用替普罗单抗或与其他药物联合使用。在15项研究中，8项研究在TED患者中使用了替普罗单抗，而其余7项研究使用了标准治疗方案。本系统评价概述了在TED患者中使用单克隆抗体——替普罗单抗和IVMP的现有治疗选择。总体评估结果表明，与传统的IVMP相比，抗体——替普罗单抗是为TED患者提供更好疗效的一个不错选择。
